References
- Chopra I, Hesse L, O'Neill AJ. Exploiting current understanding of antibiotic action for discovery of new drugs. I App!. Microbial. Symp. SuppL 92,4S-15S (2002).
- Cohen ML. Changing patterns of infectious disease. Nature 406,762–767 (2000).
- Coates A, Hu Y, Bax R, et al The future challenges facing the development of new antimicrobial drugs. Nature Rev. Drug-Disc. 1,895–910 (2002).
- Plowman R, Graves N, Griffin MA, et al The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialities of a district general hospital in England and the national burden imposed. I Hasp. Infect. 47, 198–209 (2001).
- Pfaller MA, Jones RN, Doern GV, et al Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42, 1762–1770 (1998).
- Public Health Laboratory Service. Antimicrobial Resistance in 2000: England and Wales. In: London: Public Health Laboratory Service (2002).
- Avison MB, Bennett PM, Howe RA, et al. Preliminary analysis of the genetic basis for vancomycin resistance in Staphylococcus aureus strain Mu50. Antimicrob. Chemother. 49,255–260 (2002).
- •One of the first papers to present a critical genomic analysis of the mechanisms responsible for vancomycin resistance in the VISA category.
- Centers for Disease Control. Staphylococcus auteusresistant to vancomycin — United States 2002. Nbrbid. Nbrtal Weekly RT. 51, 565–567 (2002).
- ••The first paper reporting the acquisitionof VanA by MRSA under clinical conditions.
- Centers for Disease Control. Vancomycin-resistant Staphylococcus aureus — Pennsylvania 2002. Morbid. Mortal. Weekly Rep. 51,902 (2002).
- •The second paper reporting the acquisition of VanA by MRSA under clinical conditions.
- Gonzalez-Zorn B, Courvalin P. vanA-mediated high level glycopeptide resistance in MRSA. Lancet Infect. Dis. 3, 67–68 (2003).
- Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Exp. Opin. Invest4 Drugs 8,1195-1202 (1999).
- Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207–208 (2001).
- Labischinski H, Ehlert K, Wieland B. Novel antistaphylococcal targets and compounds. Exp. Opin. Investig. Drugs 7, 1245–1256 (1998).
- Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Exp. Opin. Investig. Drugs 12, 117–137 (2003).
- ••An informative and valuable review thatcomprehensively discusses many agents that are currently in development for use as antiMRSA agents.
- Neu HC. The crisis in antibiotic resistance. Science 257,1064–1073 (1992).
- Chambers HF. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin. MicrobioL Rev 10,781–791 (1997).
- Russell AD, Chopra I. Understanding Antibacterial Action and Resistance (2nd Edition). Ellis Horwood, Chichester, UK, (1996).
- Livermore DM. Antibiotic resistance in staphylococci. Int. j Antimicrob. Agents 16, S3—S10 (2000).
- Schaaff F, Reipert A, Bierbaum G. An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 46,3540–3548 (2002).
- O'Neill AJ, Chopra I. Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low.. 1. Antimicrob. Chemother. 50, 161–169 (2002).
- •• An important paper that critically examines the theory that VISA-type vancomycin resistance arises in hypermutable staphylococci.
- O'Neill AJ, Chopra I. Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 47,1484–1485 (2003).
- Miller K, O'Neill AJ, Chopra I. Respons of Escherichia cob hypermutators to selection pressure with antimicrobial agents from different classes.Antimicrob. Chemother. 49,925–934 (2002).
- Gholizadeh Y, Courvalin P. Acquired and intrinsic glycopeptide resistance in enterococci. Int. j Antimicrob. Agents 16, S11—S17 (2000).
- Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS 11/licrobiol. Lett. 72,195-198 (1992).
- Projan SJ, Youngman PJ. Antimicrobials: new solutions badly needed. Curr. Opin. Microbial. 5,463–465 (2002).
- Pillai SK, Sakoulas G, Wennersten C, et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. Inf. Dis. 186,1603–1607 (2002).
- ••Demonstrates, somewhat unexpectedly,that multiple 23S rRNA genes are modified in linezolid resistant MRSA clinical isolates.
- Chopra I. Protein synthesis as a target for antibacterial drugs: current status and future opportunities. Exp. Opin. Investig: Drugs7, 1237–1244 (1998).
- Bayliss CD, Moxon RE. Hypermutation and bacterial adaptation. ASM News 68, 549–555 (2002).
- Lomovskaya O, Watkins W Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. MoL Microbial. BiotechnoL 3,225–236 (2001).
- Renau TE, Lemoine RC. Efflux pump inhibitors to address bacterial and fungal resistance. Drugs Future 26,1171–1178 (2001).
- Kaatz GW, Moudgal VV, Seo SM, etal Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47,719–726 (2003).
- Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology and epidemiology of bacterial resistance. MicrobioL MoL Biol. Rev 65,232–260 (2001).
- Hunter PA, Darby GK, Russell NJ (Eds), Past Perspectives and Future Trends. Cambridge University Press, Cambridge, UK, 67–84 (1996).
- Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J. Am. Acad. Dermatol 32,241–247 (1995).
- Chopra I, Brennan P Molecular action of antimycobacterial agents. Tuber. Lung-Dis. 78,89–98 (1998).
- Van Rensburg CEJ, Joone GK, O'Sullivan JF, et al Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob. Agents Chemother. 36, 2729–2735 (1992).
- De Bruyn EE, Steel HC, Van Rensburg CEJ, et al The riminophenazines, clofazimine and B669, inhibit potassium transport in Gram-positive bacteria by a lysophospholipid-dependent mechanism. Antimicrob. Chemother: 38,349–362 (1996).
- Oliva B, Commanducci A, Chopra I.Antibacterial spectra of drugs used for chemotherapy of mycobacterial infections. Tuber. Lung-Dis. 79,107–109 (1998).
- Steel HC, Matlola NM, Anderson R. Inhibition of potassium transport and growth of mycobacteria exposed toclofazimine and B669 is associated with a calcium-independent increase in microbial phospholipase A2 activity. Antimicrob. Chemother: 44,209–216 (1999).
- Chopra I. Research and development of antibacterial agents. Curr. Opin. Illicrobiol 1,495–501 (1998).
- Payne DJ, Wallis NG, Gentry DR, et al The impact of genomics on novel antibacterial targets. Current Opin. Drug Disc. Develop. 3,177–190 (2000).
- McDevitt D, Rosenberg M. Exploiting genomics to discover new antibiotics. Bends Microbial. 9,611–617 (2001).
- McDevitt D, Payne DJ, Holmes DJ, Rosenberg M. Novel targets for the future development of antibacterial agents. App!. Microbial. Symp. Suppl 92, 28S-34S (2002)
- Hackbarth CJ, Chen DZ, Lewis JG, etal. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46,2752–2746 (2002).
- Horton JR, Bostock JM, Chopra I, et al Macrocyclic inhibitors of the bacterial cell wall biosynthesis enzyme MurD. Bioorg. Med. Chem. Lett. 13,1557-1560 (2003).The first report of structure-based design of potent MurD enzyme inhibitors.
- Cramer P. Multisubunit RNApolymerases. Cun: Opin. Str. Biol. 12, 89–97 (2002).
Website
- Department of Health. Getting ahead of the curve: a strategy for combating infectious diseases. A report by the chief medical officer (2002). www.doh.gov.uldcmo/publications.htm